María José Álvarez-Pasquín
BMC Public Health · 2013
A researcher in the Science corpus: 1 paper; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Whom María José Álvarez-Pasquín trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Papers from María José Álvarez-Pasquín's perspective
Ordered by how strongly the researchers María José Álvarez-Pasquín trusts endorse each paper. Same corpus, a different order for every researcher.
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses (European Journal of Epidemiology)
- Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions (Annals of the Rheumatic Diseases)
- Evaluating non-randomised intervention studies. (Health Technology Assessment)
- Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. (Journal of the American Medical Association (JAMA))
- Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. (International Journal of Epidemiology)
- American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. (Circulation)
- Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. (Arthritis & Rheumatism)
- New therapies for treatment of rheumatoid arthritis. (The Lancet)
- Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. (The Lancet)
- Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel… (The Lancet)